tiprankstipranks
Trending News
More News >

Matinas BioPharma Approves 2025 Equity Incentive Plan

Story Highlights
Matinas BioPharma Approves 2025 Equity Incentive Plan

Don’t Miss TipRanks’ Half-Year Sale

Matinas BioPharma ( (MTNB) ) has provided an update.

On June 23, 2025, Matinas BioPharma Holdings, Inc. held its annual meeting where stockholders approved the 2025 Equity Incentive Plan, which had been previously approved by the board on April 30, 2025. The meeting also saw the election of board members and approval of executive compensation, amendments for reverse stock splits, and an increase in authorized shares, indicating strategic moves to enhance corporate governance and financial flexibility.

The most recent analyst rating on (MTNB) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Matinas BioPharma stock, see the MTNB Stock Forecast page.

Spark’s Take on MTNB Stock

According to Spark, TipRanks’ AI Analyst, MTNB is a Neutral.

The overall score reflects significant financial challenges due to declining revenues and persistent losses. Positive technical indicators provide some optimism, while valuation remains unattractive with a negative P/E ratio and no dividend yield. The recent board appointments may offer strategic improvements, but substantial progress is needed to improve financial health and stock performance.

To see Spark’s full report on MTNB stock, click here.

More about Matinas BioPharma

Average Trading Volume: 238,170

Technical Sentiment Signal: Sell

Current Market Cap: $4.64M

See more insights into MTNB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1